nc525
·Code: NC525
nc525: sourced relationships with 1 company · 1 clinical trial tracked.
nc525 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect nc525 to NXTC; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could nc525 → NXTC affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Relapsed or Refractory Acute Myeloid Leukemia
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| NextCure, Inc. (NXTC) Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Primary endpoint: To Evaluate the Frequency, Duration, and Severity of Treatment-emergent Adverse Events [Safety and Tolerability].
Interventionalopen28 targetStarted 2023-02Completion 2025-0111 sites · United StatesNextCure, Inc.
Frequently asked questions
Which companies have sourced relationships with nc525?
nc525 has dated SEC/FDA relationship records for NextCure, Inc..
How many clinical trials involve nc525?
BioSniper tracks 1 clinical trial involving nc525.